IMM Investment, Hana Ventures, and STIC Ventures are reportedly among a pool of investors that have invested KRW44b (approximately USD37m) in Curocell, a South Korea-based biotech focused on developing immune cell therapies for blood cancers. Atinum Investment, DS Asset Management, Seoul Investment Partners, Aju IB Investment, Ulmus Investment, LB Investment, Yukyung PSG Asset Management, JX Partners, Company K Partners, K2 Investment Partners, and QUAD Investment Management also took part in the investment. Read more